Skip to ContentSkip to Navigation
How to find us E.A.M. Festen

Publications

A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease

Biomarkers reflecting extracellular matrix turnover and inflammation can be used to monitor disease activity and treatment response in patients with Crohn's disease undergoing infliximab induction therapy

Cigarette smoke increases risk for colorectal neoplasia in inflammatory bowel disease

Donor genetic variants as risk factors for thrombosis after liver transplantation: A genome-wide association study

Exome sequencing in patient-parent trios suggests new candidate genes for early-onset primary sclerosing cholangitis

Genetic risk scores identify genetic aetiology of inflammatory bowel disease phenotypes

Inflammation status modulates the effect of host genetic variation on intestinal gene expression in inflammatory bowel disease

Isotype specific antibody responses to Mycobacterium Avium subspecies Paratuberculosis antigens are associated with the use of biological therapy in Inflammatory Bowel Disease

Large-scale genetic analyses in an understudied disease: haemorrhoidal disease Comment

Serological biomarkers of type III and IV collagen remodeling predict and monitor infliximab treatment response in patients with Inflammatory Bowel Disease

Read more